Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety of Right and Left Ventricular Endomyocardial Biopsy in Heart Transplantation and Cardiomyopathy Patients.
Bermpeis K, Esposito G, Gallinoro E, Paolisso P, Bertolone DT, Fabbricatore D, Mileva N, Munhoz D, Buckley J, Wyffels E, Sonck J, Collet C, Barbato E, De Bruyne B, Bartunek J, Vanderheyden M. Bermpeis K, et al. Among authors: munhoz d. JACC Heart Fail. 2022 Dec;10(12):963-973. doi: 10.1016/j.jchf.2022.08.005. Epub 2022 Oct 12. JACC Heart Fail. 2022. PMID: 36456070 Free article.
Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial.
Breder I, Wolf VLW, Soares AAS, de Carvalho LSF, Kimura-Medorima ST, Cintra RM, Barreto J, Munhoz DB, Cunha JS, Bonilha I, Coelho-Filho OR, Quinaglia T, Nadruz W, Guerra-Junior G, Muscelli E, Sposito AC; ADDENDA-BHS2 Trial Investigators. Breder I, et al. Diabetes Metab. 2022 Mar;48(2):101304. doi: 10.1016/j.diabet.2021.101304. Epub 2021 Nov 19. Diabetes Metab. 2022. PMID: 34808345 Clinical Trial. No abstract available.
Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial.
Sposito AC, Breder I, Barreto J, Breder J, Bonilha I, Lima M, Oliveira A, Wolf V, Luchiari B, do Carmo HR, Munhoz D, Oliveira D, Coelho-Filho OR, Coelho OR, Matos-Souza JR, Moura FA, de Carvalho LSF, Nadruz W, Quinaglia T, Kimura-Medorima ST; EXCEED-BHS3 Group. Sposito AC, et al. Among authors: munhoz d. Cardiovasc Diabetol. 2022 Aug 6;21(1):147. doi: 10.1186/s12933-022-01584-8. Cardiovasc Diabetol. 2022. PMID: 35933413 Free PMC article. Clinical Trial.
Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: A randomized controlled trial.
Fernandes VHR, Chaves FRP, Soares AAS, Breder I, Kimura-Medorima ST, Munhoz DB, Cintra RMR, Breder JC, Barreto J, Nadruz W, Carvalho LSF, Quinaglia T, Arieta CEL, Sposito AC; ADDENDA-BHS2 trial investigators. Fernandes VHR, et al. Diabetes Metab. 2021 Nov;47(6):101280. doi: 10.1016/j.diabet.2021.101280. Epub 2021 Sep 16. Diabetes Metab. 2021. PMID: 34537385 Clinical Trial.
Defective Allele of the Neuronal Nitric Oxide Synthase Gene Increases Insulin Resistance During Acute Phase of Myocardial Infarction.
Nóbrega OT, Campos-Staffico AM, Oliveira EK, Munhoz DB, Moura FA, Carvalho LSF, Soares AASM, Gomes CM, Tonet-Furioso AC, Sposito AC; Brasilia Heart Study and the Brasilia Heart Study Group. Nóbrega OT, et al. Int J Gen Med. 2021 Jul 20;14:3669-3676. doi: 10.2147/IJGM.S313661. eCollection 2021. Int J Gen Med. 2021. PMID: 34321912 Free PMC article.
Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial.
Breder I, Cunha Breder J, Bonilha I, Munhoz DB, Medorima STK, Oliveira DC, do Carmo HR, Moreira C, Kontush A, Zimetti F, Zanotti I, Carvalho LSF, Nadruz W, Muscelli E, Quinaglia T, Sposito AC; EXCEED-BHS3 Trial Investigator. Breder I, et al. Ther Adv Chronic Dis. 2020 Sep 28;11:2040622320959248. doi: 10.1177/2040622320959248. eCollection 2020. Ther Adv Chronic Dis. 2020. PMID: 33062236 Free PMC article.
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial.
Sposito AC, Breder I, Soares AAS, Kimura-Medorima ST, Munhoz DB, Cintra RMR, Bonilha I, Oliveira DC, Breder JC, Cavalcante P, Moreira C, Moura FA, de Lima-Junior JC, do Carmo HRP, Barreto J, Nadruz W, Carvalho LSF, Quinaglia T; ADDENDA-BHS2 trial investigators. Sposito AC, et al. Cardiovasc Diabetol. 2021 Mar 26;20(1):74. doi: 10.1186/s12933-021-01264-z. Cardiovasc Diabetol. 2021. PMID: 33771149 Free PMC article. Clinical Trial.
Compliance with Cardiovascular Prevention Guidelines in Type 2 Diabetes Individuals in a Middle-Income Region: A Cross-Sectional Analysis.
Barreto J, Luchiari B, Wolf VLW, Bonilha I, Bovi TG, Assato BS, Breder I, Kimura-Medorima ST, Munhoz DB, Quinaglia T, Coelho-Filho OR, Carvalho LSF, Nadruz W, Sposito AC. Barreto J, et al. Diagnostics (Basel). 2022 Mar 26;12(4):814. doi: 10.3390/diagnostics12040814. Diagnostics (Basel). 2022. PMID: 35453862 Free PMC article.
83 results